VascVersa is a new UK regenerative medicine company. Spinning out from Queen’s University Belfast, Vascversa is developing unique cell products for blood vessel regeneration. Our first product in development is called Angicyte. Angicyte advanced therapeutic medicinal product is highly pure and potent, with therapeutic efficacy in a range of pre-clinical disease systems such as the ischaemic retina, hindlimb and in vivo wound healing models. VascVersa is seeking to deliver Angicyte cell therapy to effectively repair damaged blood vessels and promote long lasting repair for the wound care market.